A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
收藏Mendeley Data2024-01-31 更新2024-06-27 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008901/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
创建时间：
2024-01-31
